Yotam Bar-Ephraim, PhD, LUMICKS, Amsterdam, The Netherlands, provides an overview of additional hurdles that need to be overcome to drive the development of T-cell therapies for hematological malignancies. Whilst cell avidity is vital for the efficacy of T-cells, cell viability is an additional factor to consider when assessing the quality of the product. The process of apheresis to collect T-cells also needs to be shortened to increase the viability of immunotherapies, as patients may have a limited timeframe to receive the treatment. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.